SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico
SciSparc (Nasdaq: SPRC) has announced a significant development in its collaboration with Clearmind Medicine Inc. (Nasdaq: CMND), as Clearmind secured a patent publication in Mexico for a novel combination treatment. The patent covers the innovative combination of MDMA with N-Acylethanolamines, targeting various binge behaviors including alcohol, eating, tobacco, shopping, and sexual conduct.
The treatment combines SciSparc's N-Acylethanolamines therapy with Clearmind's MEAI (5-methoxy-2-aminoindane). This collaborative research effort has resulted in 13 patent applications filed with the U.S. Patent and Trademark Office and other global jurisdictions, demonstrating the companies' commitment to developing new therapies for disorders and rare diseases of the central nervous system.
SciSparc (Nasdaq: SPRC) ha annunciato uno sviluppo significativo nella sua collaborazione con Clearmind Medicine Inc. (Nasdaq: CMND), poiché Clearmind ha ottenuto la pubblicazione di un brevetto in Messico per un nuovo trattamento combinato. Il brevetto copre l'innovativa combinazione di MDMA con N-Acilethanolamine, mirato a vari comportamenti di eccesso, tra cui alcol, alimentazione, tabacco, acquisti e condotta sessuale.
Il trattamento combina la terapia N-Acilethanolamine di SciSparc con il MEAI (5-metossi-2-aminoindano) di Clearmind. Questo sforzo di ricerca collaborativo ha portato alla presentazione di 13 domande di brevetto presso l'Ufficio Brevetti e Marchi degli Stati Uniti e altre giurisdizioni globali, dimostrando l'impegno delle aziende nello sviluppo di nuove terapie per i disturbi e le malattie rare del sistema nervoso centrale.
SciSparc (Nasdaq: SPRC) ha anunciado un desarrollo significativo en su colaboración con Clearmind Medicine Inc. (Nasdaq: CMND), ya que Clearmind ha asegurado la publicación de una patente en México para un nuevo tratamiento combinado. La patente cubre la innovadora combinación de MDMA con N-Acilethanolaminas, dirigido a varios comportamientos de consumo excesivo, incluyendo alcohol, alimentación, tabaco, compras y conducta sexual.
El tratamiento combina la terapia N-Acilethanolamina de SciSparc con el MEAI (5-metoxi-2-aminoindano) de Clearmind. Este esfuerzo de investigación colaborativa ha resultado en 13 solicitudes de patente presentadas ante la Oficina de Patentes y Marcas de EE. UU. y otras jurisdicciones globales, demostrando el compromiso de las empresas en el desarrollo de nuevas terapias para trastornos y enfermedades raras del sistema nervioso central.
SciSparc (Nasdaq: SPRC)는 Clearmind Medicine Inc. (Nasdaq: CMND)와의 협력에서 중요한 발전을 발표했습니다. Clearmind는 멕시코에서 새로운 조합 치료법에 대한 특허 출원을 받았습니다. 이 특허는 MDMA와 N-아실 에탄올아민의 혁신적인 조합을 다루고 있으며, 알코올, 음식, 담배, 쇼핑 및 성 행동 등의 다양한 폭식 행동을 목표로 하고 있습니다.
이 치료법은 SciSparc의 N-아실 에탄올아민 요법과 Clearmind의 MEAI(5-메톡시-2-아미노인단)를 결합합니다. 이 협력 연구 노력은 미국 특허청 및 기타 글로벌 관할권에 13건의 특허 출원으로 이어졌으며, 이는 중추 신경계의 질환 및 희귀 질환을 위한 새로운 요법 개발에 대한 회사의 헌신을 보여줍니다.
SciSparc (Nasdaq: SPRC) a annoncé un développement significatif dans sa collaboration avec Clearmind Medicine Inc. (Nasdaq: CMND), puisque Clearmind a obtenu une publication de brevet au Mexique pour un nouveau traitement combiné. Le brevet couvre l'innovante combinaison de MDMA avec des N-Acylethanolamines, ciblant divers comportements de consommation excessive, y compris l'alcool, l'alimentation, le tabac, les achats et la conduite sexuelle.
Le traitement combine la thérapie N-Acylethanolamines de SciSparc avec le MEAI (5-méthoxy-2-aminoindane) de Clearmind. Cet effort de recherche collaboratif a abouti à la soumission de 13 demandes de brevet auprès de l'Office américain des brevets et des marques et d'autres juridictions mondiales, démontrant l'engagement des entreprises à développer de nouvelles thérapies pour les troubles et maladies rares du système nerveux central.
SciSparc (Nasdaq: SPRC) hat eine bedeutende Entwicklung in seiner Zusammenarbeit mit Clearmind Medicine Inc. (Nasdaq: CMND) angekündigt, da Clearmind eine Patentveröffentlichung in Mexiko für eine neuartige Kombinationstherapie gesichert hat. Das Patent deckt die innovative Kombination von MDMA mit N-Acylethanolaminen ab, die verschiedene Überessverhalten wie Alkohol, Essen, Tabak, Einkaufen und sexuelles Verhalten anspricht.
Die Behandlung kombiniert SciSparcs N-Acylethanolamin-Therapie mit Clearminds MEAI (5-Methoxy-2-Aminoin-dan). Dieser kollaborative Forschungsansatz hat zur Einreichung von 13 Patentanträgen beim US-Patent- und Markenamt und in anderen globalen Jurisdiktionen geführt, was das Engagement der Unternehmen für die Entwicklung neuer Therapien für Störungen und seltene Erkrankungen des zentralen Nervensystems zeigt.
- Patent publication secured in Mexico for novel combination treatment
- 13 patent applications filed across multiple global jurisdictions
- Expansion of intellectual property portfolio in emerging markets
- None.
Insights
The publication of this patent in Mexico marks a significant milestone in SciSparc and Clearmind's intellectual property strategy, particularly noteworthy given Mexico's position as Latin America's second-largest pharmaceutical market. The patent's broad scope, covering multiple binge behaviors from alcohol to shopping addiction, suggests a potentially extensive commercial application.
The combination therapy's approach is particularly innovative, combining MDMA's established therapeutic potential with N-Acylethanolamines' neuroprotective properties. This dual-mechanism strategy could provide a significant competitive advantage in the growing mental health therapeutics market. The extensive patent portfolio, now spanning 13 patent applications across multiple jurisdictions, creates substantial barriers to entry and positions the companies favorably for future licensing or partnership opportunities.
However, investors should note several key considerations:
- The path to commercialization remains long, requiring extensive clinical trials and regulatory approvals
- The psychedelic therapeutics space is becoming increasingly competitive, with multiple companies pursuing similar indications
- Success in patent publication doesn't guarantee market exclusivity or commercial viability
- Regulatory frameworks for psychedelic-based treatments vary significantly across jurisdictions
While this patent publication strengthens the companies' intellectual property position, it represents an early-stage development in what will likely be a multi-year journey to potential commercialization.
TEL AVIV, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND) (FSE: CWY), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, Clearmind has announced the publication of a patent application in Mexico for the innovative combination of 3,4-Methylenedioxymethamphetamine (MDMA) with N-Acylethanolamines.
The patent refers to SciSparc’s innovative combination therapy of N-Acylethanolamines and Clearmind’s MEAI, (5-methoxy-2-aminoindane) addressing binge behaviour, including alcohol consumption, eating, tobacco consumption, shopping and sexual conduct.
Under this collaboration, the two companies are researching innovative combination therapies that integrate psychedelic molecules with the N-Acylethanolamines family, including Palmitoylethanolamide (PEA). To date,13 patents related to this collaboration have been filed with the U.S. Patent and Trademark Office, as well as in several other global jurisdictions.
About SciSparc Ltd. (Nasdaq: SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; and SCI-210 for the treatment of autism and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds’ oil-based products on the Amazon.com Marketplace.
About Clearmind Medicine Inc. (Nasdaq: CMND) (FSE: CWY)
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. Clearmind’s intellectual portfolio currently consists of 19 patent families including 31 granted patents. For further information visit: https://www.clearmindmedicine.com
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, the Company is using forward looking statements when discussing ongoing collaborative research, the prospective outcomes and effects of SciSparc’s collaborative research with Clearmind, and the belief that SciSparc’s approach to its research may improve treatment outcomes. Since such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in SciSparc's Annual Report on Form 20-F filed with the SEC on April 1, 2024, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055
FAQ
What is the new patent that SPRC and Clearmind received in Mexico?
How many patents has SPRC filed related to its Clearmind collaboration?
What specific compounds are included in SPRC's new combination therapy patent?
What conditions does SPRC's new patented treatment target?
